MediWound Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDWD research report →
Range $27 – $30
Price Chart
About the company
MediWound Ltd. , a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
- CEO
- Ofer Gonen
- IPO
- 2014
- Employees
- 121
- HQ
- Yavne, HM, IL
Get TickerSpark's AI analysis on MDWD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $175.45M
- P/E
- -7.47
- Fwd P/E
- 29.98
- PEG
- 0.95
- P/S
- 17.53
- P/B
- 5.54
- EV/EBITDA
- -6.24
- Div Yield
- 0.00%
- Gross Margin
- 19.54%
- Op Margin
- -337.76%
- Net Margin
- -234.98%
- ROE
- -61.68%
- ROIC
- -68.44%
Latest fiscal year · YoY change
- Revenue
- $16.96M-16.1%
- Gross Profit
- $3.25M+23.5%
- Op Income
- $-25,279,000
- Net Income
- $-23,879,000+21.0%
- EPS
- $-2.10+30.7%
- OCF Growth
- -6.7%
- FCF Growth
- -0.7%
- 52W High
- $19.70
- 52W Low
- $11.80
- 50D MA
- $13.21
- 200D MA
- $14.94
- Beta
- 0.14
- RSI (14)
- 53
- Avg Volume
- 125.80K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
MediWound said third-quarter results were pressured by lower U.S. government development revenue and higher R&D spending, while EscharEx stayed on track and NexoBrid demand remained stronger than manufacturing capacity.· November 12, 2026
- Q3 revenue was $3.6 million versus $5.4 million a year ago, with lower U.S. government development services the main driver.
- Gross profit was $1 million and gross margin improved to 28.5% from 16.5% last year, helped by higher royalty revenue.
- R&D rose to $6.2 million from $3.5 million as the company invested more in the EscharEx Phase III VALUE trial.
- Management reiterated that VALUE enrollment is on track to finish by end-1Q 2027, with top-line results expected in mid-2027.
- NexoBrid demand is outstripping supply, with more than 80 centers ordering to date and about 70 repeat ordering centers; expanded facility supply is expected in 2H 2027 pending approval.
Third-quarter 2026 revenue was $3.6 million, down from $5.4 million in the third quarter of 2025. Gross profit was $1 million, with gross margin of 28.5% versus $0.9 million and 16.5% in the prior-year period. R&D expense was $6.2 million versus $3.5 million, SG&A was $3.4 million versus $4 million, operating loss was $8.5 million versus $6.5 million, net loss was $6 million or $0.47 per share versus $2.7 million or $0.24 per share, and adjusted EBITDA loss was $7.4 million versus $5.4 million. For the first 9 months of 2026, revenue was $8.1 million versus $15.1 million, gross profit was $3 million, R&D was $17.3 million, SG&A was $10.8 million, operating loss was $26 million, net loss was $16.3 million or $1.27 per share, and adjusted EBITDA loss was $22.7 million. Cash, cash equivalents and deposits were $28.4 million as of September 30, 2026, cash burn in the first 9 months was $28.3 million, warrant exercises generated $2 million during the first 9 months and $1.1 million after quarter end, and the company closed an underwritten public offering in November 2026 for gross proceeds of $17.25 million. Management said the 2026 revenue outlook depends on ongoing discussions with the U.S. government around funding for the planned U.S.-based manufacturing facility; a substantial portion of anticipated 2026 revenue is tied to those development services.
Ofer Gonen emphasized three priorities: completing the VALUE interim assessment and enrollment by end-1Q 2027, supporting NexoBrid commercial growth, and expanding manufacturing capacity. He said the VALUE DSMB had already found no safety concerns and that the company remains comfortable with the 216-patient target, with top-line data expected in mid-2027 if the base case holds. On NexoBrid, he highlighted strong U.S. commercial momentum, BARDA-backed government procurement, and the strategic importance of the expanded facility, while also noting that the planned U.S.-based manufacturing facility remains a key uncertainty for 2026 revenue.
Hani Luxenburg said the revenue mix remains heavily weighted toward U.S. government development services, while product sales are supply-constrained and the company is selling every unit it can manufacture. She attributed the Q3 revenue decline to lower development-service revenue and the gross margin improvement to a higher mix of royalty revenue. She also pointed to increased R&D spending on VALUE, lower SG&A from reduced marketing, and the balance-sheet update: $28.4 million in cash, cash equivalents and deposits, $28.3 million of cash burn in the first 9 months, plus $2 million from warrant exercises and $1.1 million received after quarter end, followed by the $17.25 million gross proceeds from the November offering.
Analysts focused on confidence in VALUE enrollment timing, the path to the mid-2027 readout, and the strategy for EscharEx partnering. Management said about 95% of sites are open and that it is very comfortable with the end-1Q 2027 enrollment target, with the DSMB review schedule including an early-January safety review and a later first-quarter meeting that will also handle the interim sample size reassessment. On partnering, management would not comment on specific discussions, but argued EscharEx is attractive because reimbursement dynamics have shifted, it is a late-stage BLA candidate, and the opportunity could be about $1 billion in U.S. peak sales across VLU, DFU and pressure ulcers. Questions on the expanded NexoBrid facility centered on remaining validation and inspection steps; management said it expects the work to finish in Q4 2026, after which there will be review and on-site inspection before commercial supply, targeted for 2H 2027.
The call suggested that EscharEx remains on schedule, with no safety concerns from the DSMB, enrollment still tracking to finish by end-1Q 2027, and top-line data expected in mid-2027. NexoBrid also appears to be gaining traction, with more ordering centers and repeat orders in the U.S., while BARDA procurement has started and could continue into early 2027. The recent public offering and warrant proceeds also gave the company added financial flexibility through the VALUE readout.
Near-term financials were weak, with revenue down year over year and losses widening as R&D spending increased. Management said a substantial portion of anticipated 2026 revenue depends on ongoing U.S. government funding discussions for the planned U.S.-based manufacturing facility, and it does not know when or whether that funding will be secured. NexoBrid demand is constrained by manufacturing capacity, so sales are limited by supply rather than demand until the expanded facility is approved and in operation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 74.5%
- Shares Outstanding
- 12.91M
- Float Shares
- 9.62M
of shares held by institutions
83 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Investor Ab | 872.09K | 0 |
| Yelin Lapidot Holdings Management Ltd. | 758.17K | 0 |
| Rosalind Advisors, Inc. | 749.05K | 0 |
| Price T Rowe Associates Inc | 643.63K | ▲ 2.55K |
| Blackrock, Inc. | 534.02K | ▲ 8.10K |
| Kotler Kevin | 337.24K | ▲ 337.24K |
| Sphera Funds Management Ltd. | 273.19K | 0 |
| Silverberg Bernstein Capital Management LLC | 236.03K | ▲ 7.89K |
| State Street Corp | 167.52K | ▼ 1.15K |
| Ark Investment Management LLC | 146.72K | ▲ 20.14K |
| Geode Capital Management, LLC | 136.47K | ▼ 4.57K |
| Point72 Asset Management, L.P. | 134.34K | ▲ 5.09K |
Held by 72 ETFs
Biggest fund positions in MDWD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Gonen Ofer | other | 8,168 |
| Nov 11, 26 | Gonen Ofer | other | 8,168 |
| Nov 10, 26 | SHAMIR NACHUM | other | 16,336 |
| Nov 10, 26 | SHAMIR NACHUM | other | 16,336 |
| Nov 10, 26 | Fox David Morton | other | 6,534 |
| Nov 10, 26 | Fox David Morton | other | 6,534 |
| Sep 1, 26 | Rubinstein Samuel | buy | 525 |
| Sep 1, 26 | Rubinstein Samuel | sell | 525 |
| Aug 26, 26 | Hess Shmuel | other | 5,000 |
| Aug 27, 26 | Hess Shmuel | other | 11,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDWD coverage
Recent articles, reports, and earnings notes.
No research on MDWD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MDWD report →MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026
globenewswire.com · Nov 16
What MediWound (MDWD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
MediWound Ltd. (MDWD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 12
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 12
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
globenewswire.com · Nov 5
MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?
zacks.com · Nov 5
MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.